Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report

Acquired resistance inevitably occurs after initial treatment with first‐generation EGFR‐tyrosine kinase inhibitors (TKIs). Several mechanisms have been identified, including EGFR T790M mutation and HER2 amplification. Herein, we present the case of a patient who progressed on first‐generation EGFR‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ping, Nie, Xin, Wang, Bing, Li, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275817/
https://www.ncbi.nlm.nih.gov/pubmed/30295016
http://dx.doi.org/10.1111/1759-7714.12889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275817/
https://www.ncbi.nlm.nih.gov/pubmed/30295016
http://dx.doi.org/10.1111/1759-7714.12889

Ejemplares similares